- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06862193
Effectiveness of Digital Intervention (HM4MH-app) on Perinatal Psychological Wellbeing
The Effectiveneness of a Digital Intervention (the HM4MH-app) on Perinatal Psychological Wellbeing: Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As many as 25% of pregnant women report mental health problems such as depressiveness and anxiety. This is a major concern as mental illness during pregnancy can have severe and long-lasting consequences for the pregnant woman, the baby, as well as the partner. Digital interventions (e.g., apps) have shown to be promising in promoting mental wellbeing, at scale, however, the majority of tools have been developed and evaluated in a general population rather than tailored for pregnancy. The objective of this trial is therefore to investigate the effectiveness of a new digital tool (HealthyMoms4MentalHealth-app) on mental health outcomes during the perinatal period. The tool has been developed tailored to the pregnancy and postpartum period.
The study is a two-arm parallel groups multi-centre randomised controlled trial where pregnant women (n=750) will be randomised (1:1) to either an intervention (HealthyMoms4MentalHealth-app) or control group (HealthyMoms-app). Primary outcome (mental wellbeing) and secondary outcomes (resilience, depressiveness, attachment, fear of childbirth) together with mediators (self-compassion and physical activity) will be measured at baseline (gestational week 10-12), timepoint 1 (gestational week 35-38) and timepoint 2 (8-10 weeks postpartum). Baseline will also assess demographic data (age, employment, education, birth country, living situation and number of children). Stressful life events will also be measured as potential confounding variable at baseline and timepoint 2 (8-10 weeks postpartum). In addition, information on obstetric and neonatal outcomes will be collected as continuous variables or incidence from medical records (Obstetrix®Cerner). They include gestational weight gain, caesarean section, infant birth weight and length and incidence of large-for gestational-age infant (birth weight >90th percentile for gestational age and gender).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kristin Thomas Associate professor Thomas, PhD
- Phone Number: +46722072203
- Email: kristin.thomas@ki.se
Study Locations
-
-
-
Jönköping, Sweden
- Recruiting
- Region Jönköping
-
Kalmar, Sweden
- Recruiting
- Region Kalmar
-
Malmo, Sweden
- Recruiting
- Region Skane
-
Stockholm, Sweden
- Recruiting
- Region Stockholm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
(i) pregnant women attending a participating maternity health care centre who (ii) have access to their own mobile phone and BankID and is (iii) currently in gestational week 8-15 and (iv) is 18 years or older.
Exclusion Criteria:
- Previous psychotic disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: HealthyMoms (control group)
The control is a mobile application targeting women during the perinatal period, focusing on healthy lifestyles.
|
Digital intervention focusing on lifestyle behaviours during the perinatal period.
|
|
Experimental: Intervention: HealthyMoms4MentalHealth
The intervention is a mobile application targeting women during the perinatal period, aiming to promote mental wellbeing.
|
The intervention is a mobile application targeting women during the perinatal period, aiming to promote mental wellbeing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Resilience
Time Frame: Baseline (gestational weeks 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum)
|
Resilience will be measured using the Connor-Davidson Resilience Scale (CD-RISC-10) which includes 10 items graded on a five-point scale from "not at all true" to "almost always true".
The items assess various aspects of resilience, such as emotional regulation, optimism, personal strength, and the ability to manage stress.
Lower scores suggest lower resilience and possibly a greater vulnerability to stress and adversity whereas higher scores suggest higher resilience, meaning the individual is likely to be better equipped to handle stress or challenges.
|
Baseline (gestational weeks 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive symptoms
Time Frame: Baseline (gestational week 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum)
|
The Edinburgh Postpartum Depression Scale The Edinburgh Postpartum Depression Scale includes ten items graded on a four-point ordinal scale in which higher scores indicate increased depressive symptoms (range 0-30). The clinical cut-off used in Sweden for postpartum depression is >12. |
Baseline (gestational week 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum)
|
|
Mental wellbeing
Time Frame: Baseline (gestational week 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum)
|
Mental wellbeing will be measured with the Ryff Scales of Psychological Well-Being (RPWB), which includes 18 items.
For this scale, higher scores indicate greater psychological well-being (range 18-108) and responses are given on a six-point Likert scale from "strongly disagree" to "strongly agree".
|
Baseline (gestational week 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum)
|
|
Prenatal attachment
Time Frame: Timepoint 1 (gestational week 35-37)
|
Prenatal Attachment Inventory (PAI) Prenatal Attachment Inventory assess emotional attachment to the fetus using 21 items. Responses are made on a four-point likert scale and scores may range from 21 to 84 with higher scores indicating increased attachment quality/intensity. |
Timepoint 1 (gestational week 35-37)
|
|
Postpartum attachment
Time Frame: Timepoint 2 (8-9 weeks post-partum)
|
Postpartum bonding questionnaire (PBQ) The Postpartum Bonding Questionnaire is a 25 item screening questionnaire for mother-infant bonding disorders. Items are rated on a 6-point scale ranging from "Always" to "Never." |
Timepoint 2 (8-9 weeks post-partum)
|
|
Parental self-efficacy
Time Frame: Timepoint 2 (8-9 weeks post-partum)
|
Parental self-efficacy The parental self-efficacy scale is a 17 item questionniare measuring parental self-efficacy with responses on a 7 point likert scale ranging from strongly disagree to strongly agree. Higher scores indicate higher self-reported parental self-efficacy. |
Timepoint 2 (8-9 weeks post-partum)
|
|
Fear of childbirth
Time Frame: Mid-intervention (gestational week 32)
|
Fear of childbirth (FOB) The the Fear of Birth Scale (FOBS) is a short instrument that measures fear of childbirth during pregnancy. It consists of two 100 mm Visual Analogue Scales (VAS) that are summed and averaged to get a score. |
Mid-intervention (gestational week 32)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical activity
Time Frame: Weekly registrations from enrollment until intervention completion (8-9 weeks post-partum).
|
Physical activity, exercise, sedentary behaviour and screen time will be measured using six items.
Two items are questions on the degree of physical activity during work and leisure time with a three-point response scale (sedentary to active).
Four items are questions on the amount of time spent on screen time with a range from 0 to 14 hours weekly.
|
Weekly registrations from enrollment until intervention completion (8-9 weeks post-partum).
|
|
Self-compassion
Time Frame: Baseline (gestational week 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum) and mid-intervention (gestational week 18-19)
|
The Self-Compassion Scale-Short Form (SCS-SF) The Self-Compassion Scale-Short Form (SCS-SF) is a 12-item scale graded on a five-point scale from "almost never" to "almost always". Self-compassion is measured in terms of self-kindness, self-judgment, common humanity, isolation, mindfulness and over identification. |
Baseline (gestational week 12-14); timepoint 1 (gestational week 35-37); timepoint 2 (8-9 weeks post-partum) and mid-intervention (gestational week 18-19)
|
|
Stressful life events
Time Frame: Baseline (gestational week 12-14); timepoint 2 (8-9 weeks post-partum)
|
Stressful life events The Stressful Life Event Scale is a ten-item scale measuring life events such as divorce or health issues including when these events occurred (early life, during the last two years or never). |
Baseline (gestational week 12-14); timepoint 2 (8-9 weeks post-partum)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kristin Associate Professor Thomas, PhD, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM4MH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.